FibroGen Inc. [NASDAQ: FGEN] loss -5.12% or -2.25 points to close at $41.66 with a heavy trading volume of 1097534 shares. The company report on December 2, 2020 that FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting.
New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndromes (MDS) regardless of ring sideroblast (RS) or baseline erythropoietin level.
Multiple analyses evaluate cardiovascular safety and efficacy of roxadustat in patients with anemia of chronic kidney disease (CKD) regardless of dialysis status.
It opened the trading session at $43.60, the shares rose to $43.60 and dropped to $41.29, the range by which the price of stock traded the whole day. The daily chart for FGEN points out that the company has recorded 2.54% gains over the past six months. However, it is still -83.93% lower than its most recent low trading price.
If we look at the average trading volume of 659.20K shares, FGEN reached to a volume of 1097534 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about FibroGen Inc. [FGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FGEN shares is $62.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FGEN stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for FibroGen Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on October 26, 2020. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on July 10, 2020, representing the official price target for FibroGen Inc. stock. Previously, the target price had yet another raise to $40, while Cowen analysts kept a Market Perform rating on FGEN stock.
The Average True Range (ATR) for FibroGen Inc. is set at 2.01, with the Price to Sales ratio for FGEN stock in the period of the last 12 months amounting to 31.21. The Price to Book ratio for the last quarter was 8.35, with the Price to Cash per share for the same quarter was set at 7.70. Price to Free Cash Flow for FGEN in the course of the last twelve months was 91.93 with Quick ratio for the last quarter at 6.10.
Trading performance analysis for FGEN stock
FibroGen Inc. [FGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.35. With this latest performance, FGEN shares dropped by -1.02% in over the last four-week period, additionally plugging by 2.54% over the last 6 months – not to mention a drop of -12.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FGEN stock in for the last two-week period is set at 50.12, with the RSI for the last a single of trading hit 50.46, and the three-weeks RSI is set at 49.66 for FibroGen Inc. [FGEN]. The present Moving Average for the last 50 days of trading for this stock 42.42, while it was recorded at 41.58 for the last single week of trading, and 39.93 for the last 200 days.
FibroGen Inc. [FGEN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and FibroGen Inc. [FGEN] shares currently have an operating margin of -34.81 and a Gross Margin at +91.19. FibroGen Inc.’s Net Margin is presently recorded at -30.00.
Return on Total Capital for FGEN is now -14.46, given the latest momentum, and Return on Invested Capital for the company is -13.01. Return on Equity for this stock declined to -15.01, with Return on Assets sitting at -8.86. When it comes to the capital structure of this company, FibroGen Inc. [FGEN] has a Total Debt to Total Equity ratio set at 12.32. Additionally, FGEN Total Debt to Total Capital is recorded at 10.97, with Total Debt to Total Assets ending up at 7.42. Long-Term Debt to Equity for the company is recorded at 9.74, with the Long-Term Debt to Total Capital now at 8.67.
Reflecting on the efficiency of the workforce at the company, FibroGen Inc. [FGEN] managed to generate an average of -$144,953 per employee. Receivables Turnover for the company is 2.36 with a Total Asset Turnover recorded at a value of 0.30.FibroGen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.20.
FibroGen Inc. [FGEN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, FibroGen Inc. posted -1.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.59/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -89.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FGEN.
An analysis of insider ownership at FibroGen Inc. [FGEN]
There are presently around $2,870 million, or 76.80% of FGEN stock, in the hands of institutional investors. The top three institutional holders of FGEN stocks are: BLACKROCK INC. with ownership of 7,533,050, which is approximately -5.223% of the company’s market cap and around 1.00% of the total institutional ownership; VANGUARD GROUP INC, holding 7,369,115 shares of the stock with an approximate value of $307.0 million in FGEN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $295.12 million in FGEN stock with ownership of nearly 29.226% of the company’s market capitalization.
Positions in FibroGen Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 105 institutional holders increased their position in FibroGen Inc. [NASDAQ:FGEN] by around 5,470,852 shares. Additionally, 97 investors decreased positions by around 3,800,805 shares, while 32 investors held positions by with 59,611,156 shares. The mentioned changes placed institutional holdings at 68,882,813 shares, according to the latest SEC report filing. FGEN stock had 36 new institutional investments in for a total of 1,584,844 shares, while 23 institutional investors sold positions of 626,998 shares during the same period.